Meclizigo 25 mg

Trade Name:

Meclizigo 25 mg

Motion sickness relief

Properties

Meclizine is a first-generation antihistamine (non-selective H1 antagonist). It also has central anticholinergic actions.The blocking actions on these receptors give meclizine its antiemetic and antivertigo properties. This blocking effect occurs in the vomiting center and chemoreceptor trigger zone (CTZ) located in the medulla. These effects result in the inhibition of signals through histamine neurotransmission from the nucleus of the solitary tract and the vestibular nuclei to the chemoreceptor trigger zone and vomiting center located in the medulla. This effect also reduces vestibular incitation and labyrinth excitability.

Indications

*Symptomatic management of motion sickness. These symptoms include dizziness, nausea, and vomiting. It also treats vertigo symptoms caused by vestibular diseases that commonly affect the inner ear, such as Meniere’s disease. Meclizine can also be an option to treat the same symptoms caused by viral illnesses, gastrointestinal infections, pregnancy, or radiation therapy.

Dosage and administration

The drug can be taken orally with or without food.

Recommended dosage to control motion sickness is between 25 to 50 mg one hour before embarkation for protection against motion sickness — additional dosages are repeatable once every 24 hours. The recommended dosage for control of vertigo against vestibular diseases is between 25 to 100 mg daily, and subsequent dosages depend upon clinical response.

Warnings and precautions:

Side effects

Common: drowsiness, urinary retention, dry mouth, headache, fatigue, and vomiting.On rare occasions, there have been reports of blurred vision and anaphylactic reactions.

Contraindications

Meclizine is contraindicated in individuals with a history of hypersensitivity to the drug or any of the inactive ingredients.

Storage

Store at a temperature not exceeding 30°C

Package:

Carton box holds 20 individually packed oral dissolvable films, paper instructions.